Cadrenal Therapeutics, Inc.
Last verified 2026-05-18. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $4.4Mattributed |
|---|---|
| Latest round | Funding round, $4.4M, 2025-12-16attributed |
| Founded | 2022 |
| Headquarters | Ponte Vedra, Florida |
| Industry | bio |
| Stage | unknown |
| Website | cadrenal.com |
Cadrenal Therapeutics develops therapies for life-threatening immune and thrombotic conditions, including CAD-1005, a 12-LOX inhibitor for heparin-induced thrombocytopenia. It targets patients with rare cardiovascular and kidney diseases who lack effective options. Unlike existing HIT therapies, CAD-1005 addresses the underlying cause.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-16 | Funding round | $4.4M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Yoast SEO 24.0, jQuery Migrate 3.4.1, Elementor 4.0.9, Elementor Addon Elements 1.0, Cloudflare Bot Management, Cookie Notice 3.0.2, WP Engine, Python, PHP, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $4.4M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $4.4M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | cadrenal.com, read 2026-05-18 |
| Description | self-reported | cadrenal.com, read 2026-05-18 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $4.4M, 2025-12-16 → Funding round, $4.4M, 2025-12-16, sec-edgar, No document URL on file | Latest round | seed, $4.4M, 2025-12-16 → Funding round, $4.4M, 2025-12-16 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes